Navigation Links
Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
Date:3/25/2013

WASHINGTON, March 25, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the company held a pre-NDA meeting with the Division of Neurology Products of the U.S. Food and Drug Administration (FDA) to discuss the regulatory path for filing a New Drug Application (NDA) for tasimelteon, a circadian regulator, for the treatment of Non-24-Hour Disorder (Non-24).  Non-24 is a serious, rare circadian rhythm disorder that affects a majority of totally blind individuals.  Currently there is no FDA approved treatment for Non-24.

At the pre-NDA meeting, the FDA confirmed that the efficacy and safety data proposed by Vanda to be submitted in the tasimelteon NDA for Non-24 is adequate to support filing.  The NDA supporting package that includes data from clinical pharmacology, pre-clinical pharmacology program, chemistry and manufacturing was also deemed adequate to support filing.

"We are pleased with the positive interaction we had with the FDA as we are moving closer to providing a treatment for blind individuals with Non-24," said Mihael H. Polymeropoulos , M.D., President and CEO of Vanda. 

Based on this successful completion of the pre-NDA meeting, Vanda is targeting an NDA submission for tasimelteon in mid-2013.

About Vanda Pharmaceuticals Inc.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda, please visit www.vandapharma.com.   

Company Contact:
Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com

Media Contact:
Laney Cohen
Account Supervisor
Makovsky & Company, Inc.
(212)-508-9643
lcohen@makovsky.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "project," "target," "goal," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.  Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: the inability to reach agreement with the FDA regarding Vanda's regulatory approval strategy or proposed path to approval for tasimelteon for the treatment of Non-24-Hour Disorder; Vanda's failure to obtain regulatory approval for tasimelteon for the treatment of Non-24-Hour Disorder or to comply with ongoing regulatory requirements; and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2012 which is on file with the SEC and available on the SEC's website at www.sec.gov.  In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results.  There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda.  Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein.  Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf.  The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
2. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
3. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
4. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
5. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
6. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
7. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
8. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
9. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
10. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
11. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced financial ... unless otherwise noted, are to the quarter ended June 30, ... 2017 Highlights include: Revenue of $1,126 ... Total prescriptions dispensed of 220,000, compared to 241,000 ... Gross profit per prescription dispensed of $371, ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
(Date:8/2/2017)... , Aug. 2, 2017   Marshall County Hospital in Benton, Kentucky ... reduce the risk of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short ... to kill deadly pathogens such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today announces the launch ... lifestyles and highlighting the importance of proactive eye and ear health. The campaign ... latest innovations in hearing aid technology. , In this issue, the American ...
(Date:8/18/2017)... ... 18, 2017 , ... Radabaugh & Associates, a family managed ... North-Central West Virginia, is embarking on a cooperative charity effort with the Chestnut ... The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for young men ...
(Date:8/18/2017)... ... August 18, 2017 , ... Goss & Associates Insurance Agency, ... commercial clients in the greater Houston region, is helping locally recognized nonprofit Addi’s ... against cancer. , Founded by Tony and Amber Bender after losing their young ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... says will lift the veil on false teachings pertaining to the mother of the Savior ... teach, you see a far different picture of the role of this historical woman. ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Our Mountains to Climb: A ... a couple that grew stronger together through the faith they shared to overcome struggles ... is the creation of published author, Barbara J. Corcoran, a retired teacher and happily ...
Breaking Medicine News(10 mins):